Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index.

New insights into atypical Alzheimer's disease in the era of biomarkers

Open access

Abstract

Most patients with Alzheimer's disease present with amnestic problems; however, a substantial proportion, over-represented in young-onset cases, have atypical phenotypes including predominant visual, language, executive, behavioural, or motor dysfunction. In the past, these individuals often received a late diagnosis; however, availability of CSF and PET biomarkers of Alzheimer's disease pathologies and incorporation of atypical forms of Alzheimer's disease into new diagnostic criteria increasingly allows them to be more confidently diagnosed early in their illness. This early diagnosis in turn allows patients to be offered tailored information, appropriate care and support, and individualised treatment plans. These advances will provide improved access to clinical trials, which often exclude atypical phenotypes. Research into atypical Alzheimer's disease has revealed previously unrecognised neuropathological heterogeneity across the Alzheimer's disease spectrum. Neuroimaging, genetic, biomarker, and basic science studies are providing key insights into the factors that might drive selective vulnerability of differing brain networks, with potential mechanistic implications for understanding typical late-onset Alzheimer's disease.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(20)30440-3

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 102 references

Cited by

See all 814

Metadata

Authors
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E.
Affiliations
  • UCL Queen Square Institute of Neurology (GB)
  • Indiana University School of Medicine (US)
  • Amsterdam University Medical Centers (NL)
  • Harvard University (US)
  • University of California, San Francisco (US)
  • Mayo Clinic (US)
  • Mayo Clinic in Florida (US)
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2021-03
Volume
20
Issue
3
Pages
222-234
ISSN
1474-4422 (ISSN-L)
OpenAlex
W3131646863
Cited by
706
References
102
Citations by year
2026: 129 · 2025: 214 · 2024: 163 · 2023: 109 · 2022: 67 · 2021: 24
FWCI
16.25
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • PubMed Central (acceptedVersion)
  • Purdue University Indianapolis (Indiana University) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
National Institute on Aging
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
atypical Alzheimer's disease, cerebrospinal fluid biomarkers, PET biomarkers, early diagnosis, diagnostic criteria, early-onset Alzheimer's disease, inclusion and exclusion criteria, amnestic Alzheimer's disease
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Biomarkers, Age of Onset, Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New insights into atypical Alzheimer's disease in the era of biomarkers. https://app.cochat.ai/papers/10.1016/s1474-4422(20)30440-3
The paper
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E. (2021). New insights into atypical Alzheimer's disease in the era of biomarkers. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(20)30440-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.